Program
remibrutinib
Also written as “Remibrutinib”, “LOU064” and “LOU064 (blinded)”.
Its studies are mostly in Chronic Urticaria · Hidradenitis Suppurativa · Pruritus · Rosacea · Food Hypersensitivity, led by Novartis.
Drug pageRemibrutinib: every studyAll 35 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 3421 open or running | phase 3since Aug 19, 2021 | Dec 14, 2015 | Feb 22, 2027phase 3 · NCT06868212 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 18 earlier studies, Dec 14, 2015 to Sep 7, 2023.
- Jun 9, 2019Named remibrutinibINNProposed as its International Nonproprietary Name in WHO's List 121 · before, LOU064
- Dec 17, 2024Phase 3 study in Myasthenia GravisNCT06744920 · 180 enrolled · United States, Argentina, Australia and more
- Jan 23, 2025Phase 3 study in Hidradenitis SuppurativaNCT06799000 · 588 enrolled · United States, Argentina, Australia and more
- Feb 17, 20252 phase 3 studiesNCT06840392, NCT06846281
- Mar 6, 2025Phase 3 study in Chronic UrticariaNCT06868212 · 409 enrolled · United States
- Mar 6, 2025Phase 2 study in Chronic UrticariaNCT06865651 · 44 planned · United States, France, Germany and more
- Jun 19, 2025Phase 1 study in Renal InsufficiencyNCT07032272 · 16 enrolled · United States
- Nov 4, 2025Phase 3 study in Multiple Sclerosis, Chronic ProgressiveNCT07225504 · 1,275 planned · United States, Argentina, Australia and more
- Mar 3, 2026Phase 3 study in Indication of the Parent ProtocolNCT07456891 · 650 planned · Bulgaria, Canada, Colombia and more
- Jun 18, 2026Phase 3 study in Hidradenitis SuppurativaNCT07665437 · 710 planned · United States, Argentina, Australia and more
- Jun 26, 2026Phase 2 study in RosaceaNCT07681271 · 100 planned · United States, Bulgaria, Canada and more
- Jul 7, 2026Phase 3 study in Chronic Pruritus of Unknown OriginNCT07700056 · 180 planned · United States, Argentina, Canada and more
- Aug 12, 2026Phase 3 study in Food HypersensitivityNCT07768371 · 576 planned · United States
- Sep 4, 20262 phase 3 studiesNCT07811869, NCT07816328
- Sep 28, 2026Phase 1 study in Hidradenitis SuppurativaNCT07855276 · 30 planned · United States
Ahead
- Nov 3, 2026Primary completion: phase 3 study in Chronic UrticariaNCT05677451
- Feb 22, 2027Primary completion: phase 3 study in Chronic UrticariaNCT06868212
- May 17, 2027Primary completion: phase 3 study in Hidradenitis SuppurativaNCT06799000
- Jun 3, 2027Primary completion: phase 3 study in Hidradenitis SuppurativaNCT06840392
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 34 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07855276Hidradenitis Suppurativa · United States | 1 | Recruiting | Nov 29, 2027 | 30 |
| NCT07816328Chronic Urticaria · Canada, Hong Kong, Japan and more | 3 | Recruiting | May 24, 2028 | 382 |
| NCT07811869Chronic Pruritus of Unknown Origin · United States, Canada, China | 3 | Recruiting | Feb 26, 2029 | 180 |
| NCT07768371Food Hypersensitivity · United States | 3 | Recruiting | Mar 30, 2029 | 576 |
| NCT07700056Chronic Pruritus of Unknown Origin · United States, Argentina, Canada and more | 3 | Recruiting | Dec 19, 2029 | 180 |
| NCT07681271Rosacea · United States, Bulgaria, Canada and more | 2 | Recruiting | Dec 7, 2027 | 100 |
| NCT07665437Hidradenitis Suppurativa · United States, Argentina, Australia and more | 3 | Recruiting | Oct 15, 2031 | 710 |
| NCT07456891Indication of the Parent Protocol · Bulgaria, Canada, Colombia and more | 3 | Recruiting | Jan 30, 2033 | 650 |
| NCT07225504Multiple Sclerosis, Chronic Progressive · United States, Argentina, Australia and more | 3 | Recruiting | Dec 3, 2030 | 1,275 |
| NCT07032272Renal Insufficiency · United States | 1 | Completed | Oct 12, 2025 | 16 |
| NCT06868212Chronic Urticaria · United States | 3 | Active, not recruiting | Feb 22, 2027 | 409 |
| NCT06865651Chronic Urticaria · United States, France, Germany and more | 2 | Recruiting | Aug 23, 2027 | 44 |
| NCT06846281Relapsing Multiple Sclerosis · United States, Argentina, Australia and more | 3 | Recruiting | Jul 25, 2029 | 400 |
| NCT06840392Hidradenitis Suppurativa · United States, Argentina, Austria and more | 3 | Active, not recruiting | Jun 3, 2027 | 565 |
| NCT06799000Hidradenitis Suppurativa · United States, Argentina, Australia and more | 3 | Active, not recruiting | May 17, 2027 | 588 |
| NCT06744920Myasthenia Gravis · United States, Argentina, Australia and more | 3 | Active, not recruiting | Feb 25, 2028 | 180 |
| NCT06042478Chronic Urticaria · Argentina, Brazil, Bulgaria and more | 3 | Active, not recruiting | Sep 17, 2025 | 470 |
| NCT05976243Chronic Inducible Urticaria · United States, Argentina, Australia and more | 3 | Active, not recruiting | May 11, 2026 | 362 |
| NCT05795153Chronic Urticaria · United States, Argentina, Canada and more | 3 | Completed | Apr 25, 2024 | 144 |
| NCT05677451Chronic Urticaria · United States, Argentina, Canada and more | 3 | Active, not recruiting | Nov 3, 2026 | 100 |
| NCT05753592Hepatic Impairment · Hungary | 1 | Completed | Dec 14, 2023 | 38 |
| NCT05513001Chronic Urticaria · United States, Argentina, Australia and more | 3 | Active, not recruiting | Aug 26, 2024 | 696 |
| NCT05432388Peanut Hypersensitivity · United States | 2 | Completed | Mar 11, 2025 | 76 |
| NCT05156281Recurrence · United States, Argentina, Brazil and more | 3 | Active, not recruiting | Jul 22, 2026 | 1,007 |
| NCT05147220Recurrence · United States, Argentina, Austria and more | 3 | Active, not recruiting | Jul 21, 2026 | 1,000 |
| NCT05048342Chronic Urticaria · Japan | 3 | Completed | Dec 8, 2023 | 71 |
| NCT05032157Chronic Urticaria · United States, Austria, Brazil and more | 3 | Completed | Dec 18, 2023 | 455 |
| NCT05030311Chronic Urticaria · United States, Argentina, Australia and more | 3 | Completed | Dec 27, 2023 | 470 |
| NCT04109313Chronic Urticaria · United States, Argentina, Belgium and more | 2 | Completed | Sep 9, 2022 | 229 |
| NCT04035668Sjogren's Syndrome · United States, Australia, Belgium and more | 2 | Terminated | Nov 23, 2021 | 73 |
| NCT03944707Asthma · United States, Argentina, Germany and more | 2 | Terminated | Apr 27, 2020 | 76 |
| NCT03926611Chronic Urticaria · United States, Argentina, Belgium and more | 2 | Completed | Jan 14, 2021 | 311 |
| NCT03827798Hidradenitis Suppurativa · United States, Austria, Belgium and more | 2 | Completed | Dec 4, 2024 | 248 |
| NCT03918980Dermatitis, Atopic · Germany, Netherlands | 1 | Completed | Jan 27, 2020 | 185 |
How it is read
Names in the registry
- “Remibrutinib”, 13 entries
- “LOU064”, 7 entries
- “LOU064 (blinded)”, 3 entries
- “Remibrutinib Dose A”, 2 entries
- “Remibrutinib Dose B”, 2 entries
Conditions, from the studies’ own filings
- Chronic Urticaria, 12 studies
- Hidradenitis Suppurativa, 5 studies
- Pruritus, 2 studies
- Rosacea, 1 study
- Food Hypersensitivity, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.